Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Piotroski F-score
Viatris Inc.'s Piotroski F-score for fiscal 2025 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 4 | 0.00 |
| FY2024 | 4 | (4.00) |
| FY2023 | 8 | 1.00 |
| FY2022 | 7 | 3.00 |
| FY2021 | 4 | 1.00 |
| FY2020 | 3 | (2.00) |
| FY2019 | 5 | (1.00) |
| FY2018 | 6 | 1.00 |
| FY2017 | 5 | 2.00 |
| FY2016 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (8.93%) | (1.42%) | Fail | 0 |
| Positive operating cash flow | 2.32b | 2.30b | Pass | 1 |
| Rising return on assets | (8.93%) | (1.42%) | Fail | 0 |
| Cash flow above net income | 5.83b | 2.94b | Pass | 1 |
| Falling long-term leverage | 0.37 | 0.36 | Fail | 0 |
| Rising current ratio | 1.38 | 1.65 | Fail | 0 |
| No new shares issued | 1,170,700,000 | 1,193,300,000 | Pass | 1 |
| Rising gross margin | 35.06% | 38.15% | Fail | 0 |
| Rising asset turnover | 0.36 | 0.33 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| UTHR United Therapeutics Corporation compare | 8 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 8 |
| HLN Haleon PLC Sponsored ADR compare | 8 |
| ZTS Zoetis Inc. compare | 7 |
| NBIX Neurocrine Biosciences, Inc. compare | 7 |
| ELAN Elanco Animal Health Incorporated compare | 5 |
| RDY Dr. Reddy's Laboratories Ltd compare | 4 |
| TAK Takeda Pharmaceutical Co. compare | 4 |
| VTRS Viatris Inc. | 4 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement